Aardvark Therapeutics, Inc. (AARD)
5.38
-0.35
(-6.11%)
USD |
NASDAQ |
Sep 04, 16:00
5.19
-0.19
(-3.53%)
After-Hours: 20:00
Aardvark Therapeutics Total Liabilities (Quarterly) : 6.663M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.663M |
| March 31, 2026 | 11.60M |
| December 31, 2025 | 10.55M |
| September 30, 2025 | 10.85M |
| June 30, 2025 | 10.55M |
| March 31, 2025 | 6.336M |
| Date | Value |
|---|---|
| December 31, 2024 | 132.15M |
| September 30, 2024 | 3.157M |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | 45.34M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 896.90M |
| Corcept Therapeutics, Inc. | 182.93M |
| Veru, Inc. | 8.651M |
| Johnson & Johnson | 116.09B |
| Eli Lilly & Co. | 108.40B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 81.46M |
| Shareholders Equity (Quarterly) | 74.80M |
| Debt to Equity Ratio | 0.0091 |
| Current Ratio | 12.63 |
| Net Debt Paydown Yield | 0.01% |